Compass Associates
Multi-award-winning recruitment consultancy dedicated to the independent Health, Social Care and Children's Services sectors.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
Novartis has announced that its investigational immunotherapy spartalizumab in combination with Tafinlar (dabrafenib) and Mekinist (trametinib) failed to improve progression-free survival in patients with advanced melanoma.